DWIGHT WILLIAMS: Open Payments
NPI 1619930591 · PARAGOULD, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$567 in 29 payments from 10 companies in 2025. Trend: 2023 $666 · 2024 $671 · 2025 $567
Food & beverage: $567
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $156 |
| ABBVIE INC. | 12 | $135 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| Novo Nordisk Inc | 4 | $62 |
| GlaxoSmithKline, LLC. | 2 | $28 |
| GENZYME CORPORATION | 1 | $24 |
| Tris Pharma Inc | 1 | $17 |
| PFIZER INC. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
Products named: BREZTRI, REXULTI, UBRELVY, VRAYLAR, Ozempic, QULIPTA, TRELEGY ELLIPTA, FABRAZYME.
Industry payments across AR — which companies pay providers there.
